$BIAF
bioAffinity Technologies, Inc. Stock $biaf

$biaf Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019615 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$2.398M	$2.406M	$921.00
YoY Change	12047.39%	261180.24%
Cost Of Revenue	$1.408M	$1.573M	$87.00
YoY Change	113976.99%	1808451.72%
Gross Profit	$989.9K	$833.0K	$834.00
YoY Change	5249.87%	99774.1%
Gross Profit Margin	41.29%	34.61%	90.55%
Selling, General & Admin	$2.473M	$2.186M	$1.170M
YoY Change	73.35%	86.9%	231.77%
% of Gross Profit	249.79%	262.43%	140234.89%
Research & Development	$402.4K	$393.6K	$369.6K
YoY Change	20.08%	6.5%	-1.31%
% of Gross Profit	40.65%	47.26%	44318.59%
Depreciation & Amortization	$40.24K	$38.81K	$22.00K
YoY Change	91.63%	76.41%	2015.38%
% of Gross Profit	4.07%	4.66%	2637.89%
Operating Expenses	$4.485M	$4.352M	$1.559M
YoY Change	149.63%	179.16%	114.4%
Operating Profit	-$2.088M	-$1.945M	-$1.558M
YoY Change	17.4%	24.86%	114.29%
Interest Expense	-$17.06K	$23.55K	$37.00K
YoY Change	-1354.41%	-36.35%	-104.98%
% of Operating Profit
Other Income/Expense, Net	-$17.06K	-$12.91K	$37.00K
YoY Change	-139.9%	-134.9%	-103.23%
Pretax Income	-$2.105M	-$1.958M	-$1.521M
YoY Change	21.28%	28.74%	3.48%
Income Tax	$5.419K	$3.672K	$11.82K
% Of Pretax Income
Net Earnings	-$2.110M	-$1.962M	-$1.533M
YoY Change	21.27%	27.99%	4.13%
Net Earnings / Revenue	-88.01%	-81.53%	-166426.71%
Basic Earnings Per Share	-$0.19	-$0.20	-$0.18
Diluted Earnings Per Share	-$0.19	-$0.20	-$0.18
COMMON SHARES
Basic Shares Outstanding	11.66M shares	11.51M shares	8.463M shares
Diluted Shares Outstanding	11.39M shares	9.915M shares	8.434M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$801.3K	$2.453M	$9.769M
YoY Change	-90.32%	-74.89%	850.27%
Cash & Equivalents	$800.0K	$2.500M	$9.800M
Short-Term Investments
Other Short-Term Assets	$253.7K	$344.9K	$441.1K
YoY Change	-9.28%	-21.81%	579.39%
Inventory	$29.77K	$9.487K	$11.34K
Prepaid Expenses
Receivables	$1.596M	$1.124M	$11.03K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.680M	$3.931M	$10.23M
YoY Change	-69.05%	-61.58%	825.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$449.3K	$461.2K	$225.1K
YoY Change	116.63%	104.92%	6169.28%
Goodwill	$1.404M	$1.404M
YoY Change
Intangibles	$804.3K	$818.9K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$19.68K	$16.06K	$6.920K
YoY Change	184.32%	132.08%	-97.16%
Total Long-Term Assets	$3.976M	$4.118M	$232.0K
YoY Change	1755.39%	1675.14%	-6.23%
TOTAL ASSETS
Total Short-Term Assets	$2.680M	$3.931M	$10.23M
Total Long-Term Assets	$3.976M	$4.118M	$232.0K
Total Assets	$6.656M	$8.049M	$10.46M
YoY Change	-24.99%	-23.08%	673.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$848.1K	$384.0K	$146.5K
YoY Change	386.29%	162.05%	-40.84%
Accrued Expenses	$969.1K	$883.3K	$481.3K
YoY Change	87.93%	83.51%	-74.12%
Deferred Revenue
YoY Change
Short-Term Debt	$4.110K	$4.690K	$168.4K
YoY Change	-90.29%	-97.22%	-98.57%
Long-Term Debt Due	$380.3K	$372.8K
YoY Change
Total Short-Term Liabilities	$2.326M	$1.772M	$796.3K
YoY Change	200.11%	122.48%	-94.26%
LONG-TERM LIABILITIES
Long-Term Debt	$664.3K	$762.5K	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$232.7K	$258.1K
YoY Change
Total Long-Term Liabilities	$897.0K	$1.021M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.326M	$1.772M	$796.3K
Total Long-Term Liabilities	$897.0K	$1.021M	$0.00
Total Liabilities	$3.223M	$2.792M	$796.3K
YoY Change	315.83%	250.65%	-94.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$48.70M	-$46.60M	-$38.20M
YoY Change	22.06%	21.99%
Common Stock	$79.41K	$78.52K	$59.24K
YoY Change	32.59%	32.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.433M	$5.257M	$9.668M
YoY Change
Total Liabilities & Shareholders Equity	$6.656M	$8.049M	$10.46M
YoY Change	-24.99%	-23.08%	673.42%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$2.110M	-$1.962M	-$1.533M
YoY Change	21.27%	27.99%	4.13%
Depreciation, Depletion And Amortization	$40.24K	$38.81K	$22.00K
YoY Change	91.63%	76.41%	2015.38%
Cash From Operating Activities	-$1.532M	-$2.346M	-$1.529M
YoY Change	12.68%	53.43%	141.19%
INVESTING ACTIVITIES
Capital Expenditures	$28.28K	$41.39K	$32.31K
YoY Change	630.75%	28.08%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$28.28K	-$41.39K	-$32.31K
YoY Change	630.75%	28.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-91.15K	$2.019M	-$83.32K
YoY Change	-27.71%	-2523.25%	-127.65%
NET CHANGE
Cash From Operating Activities	-1.532M	-$2.346M	-$1.529M
Cash From Investing Activities	-28.28K	-$41.39K	-$32.31K
Cash From Financing Activities	-91.15K	$2.019M	-$83.32K
Net Change In Cash	-1.652M	-$368.4K	-$1.645M
YoY Change	10.87%	-77.6%	394.47%
FREE CASH FLOW
Cash From Operating Activities	-$1.532M	-$2.346M	-$1.529M
Capital Expenditures	$28.28K	$41.39K	$32.31K
Free Cash Flow	-$1.561M	-$2.387M	-$1.561M
YoY Change	14.44%	52.9%	146.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023Q1	BIAF	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset		usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2024Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization		usd
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense		usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost		usd
CY2023Q1	us-gaap	Lease Cost LeaseCost		usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41463
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	bioAffinity Technologies, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5211056
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	22211 W. Interstate 10
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1206
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Antonio
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78257
CY2024Q1	dei	City Area Code CityAreaCode	(210)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	698-5334
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11657537	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2821570	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	811674	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	18484	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321017	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3972745	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	458633	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	370312	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1165844	usd
CY2023Q4	us-gaap	Goodwill Goodwill	1404486	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	833472	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16060	usd
CY2023Q4	us-gaap	Assets Assets	8221552	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	604789	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1149811	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	33058	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94708	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	365463	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	4686	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2247829	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	835467	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283001	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	23037	usd
CY2023Q4	us-gaap	Liabilities Liabilities	3366297	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11216491	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11216491	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	65762	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49393972	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44604479	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4855255	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8221552	usd
CY2024Q1	BIAF	Direct Costs And Expenses DirectCostsAndExpenses	1573441	usd
CY2023Q1	BIAF	Direct Costs And Expenses DirectCostsAndExpenses	87	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	393639	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	369617	usd
CY2024Q1	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	48960	usd
CY2023Q1	BIAF	Clinical Development Expense ClinicalDevelopmentExpense	19628	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2185944	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1147875	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	149637	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21684	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	4351621	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1558891	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1945230	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1557970	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	6127	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	38654	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	23550	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1655	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4510	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12913	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36999	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1958143	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1520971	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3672	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11819	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1961815	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1532790	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9915426	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9915426	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8433689	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8433689	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4855255	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	283712	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	74899	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2500000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	495000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1961815	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	5257051	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11043443	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	157613	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1532790	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9668266	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	9668266	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1961815	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1532790	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	149637	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21684	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	283712	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	157613	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	311935	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	538	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-8997	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5795	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	23883	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-89847	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-220796	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-198505	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-266492	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-60557	usd
CY2024Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2884	usd
CY2024Q1	BIAF	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	516	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2345975	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1529041	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41387	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32314	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41387	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32314	usd
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	495000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2005000	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	74899	usd
CY2024Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	27723	usd
CY2023Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	83316	usd
CY2024Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	88665	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2018957	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-83316	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-368405	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1644671	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2821570	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11413759	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2453165	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9769088	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	23550	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	11819	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3672	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1655	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46600000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2500000	usd
CY2024Q1	BIAF	Percentage Of Net Assets PercentageOfNetAssets	0.30	pure
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_847_eus-gaap--UseOfEstimates_zu28THyhLQn7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation allowance on the Company’s deferred tax assets, stock-based compensation, valuation of goodwill and intangible assets related to the business combination, allowance for contractual adjustments and discounts related to service revenues, and the useful lives of fixed assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q1	us-gaap	Revenues Revenues	1806196	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	1779300	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.21
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zOphz1IvC8Z3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Risk</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_90B_eus-gaap--CashFDICInsuredAmount_iI_c20240331_zeBC1BeZQ85e" title="Federal insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flow.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1123609	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	811674	usd
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Advertising Expense AdvertisingExpense	11920	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	6049	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9457564	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5456344	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2406391	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	921	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2254486	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-31111	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2223375	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	14583	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2406391	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	921	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1945230	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1557970	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12913	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36999	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1958143	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1520971	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3672	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11819	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1961815	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1532790	usd
CY2024Q1	BIAF	Histology Fees HistologyFees	112790	usd
CY2023Q4	BIAF	Histology Fees HistologyFees	121301	usd
CY2024Q1	BIAF	Medical Director Fees MedicalDirectorFees	3040	usd
CY2023Q4	BIAF	Medical Director Fees MedicalDirectorFees	3103	usd
CY2024Q1	us-gaap	Other Receivables OtherReceivables	56143	usd
CY2023Q4	us-gaap	Other Receivables OtherReceivables	29553	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	393639	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	369617	usd
CY2024Q1	BIAF	Patient Service Fees PatientServiceFees	951636	usd
CY2023Q4	BIAF	Patient Service Fees PatientServiceFees	657717	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	1112265	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	120215	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	171855	usd
CY2024Q1	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	25042	usd
CY2023Q4	BIAF	Prepaid Legal And Professional PrepaidLegalAndProfessional	24476	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	199643	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	124686	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	344900	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321017	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	873939	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	831756	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	412730	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	373123	usd
CY2024Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y3M29D
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	461209	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	458633	usd
CY2024Q1	us-gaap	Depreciation Depreciation	38811	usd
CY2023Q1	us-gaap	Depreciation Depreciation	21685	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	670488	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	857037	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	196553	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	257926	usd
CY2024Q1	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	3356	usd
CY2023Q4	BIAF	Accrued Clinical Expense Current AccruedClinicalExpenseCurrent	15350	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12922	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	19498	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	883319	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1149811	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	30174	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	33058	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	91294	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	336378	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	121726	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	448505	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	121726	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	270395	usd
CY2024Q1	BIAF	Lessee Operating Lease Liability Payments Due Year Three And Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter	71007	usd
CY2024Q1	BIAF	Finance Lease Liability Payments Due Year Three And Thereafter FinanceLeaseLiabilityPaymentsDueYearThreeAndThereafter	202970	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	405753	usd
CY2024Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	1258248	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	51012	usd
CY2024Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	145983	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	96243	usd
CY2024Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	23550	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	29915	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	149708	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	347860	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	370312	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	96631	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	94708	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	258110	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	283001	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1294168	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1294168	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	224567	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	128324	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1069601	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1165844	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	372787	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	365463	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	739478	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	835467	usd
CY2024Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	1112265	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1200930	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M29D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y6M29D
CY2024Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y14D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0807	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0807	pure
CY2024Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0801	pure
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0801	pure
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	354741	usd
CY2024Q1	BIAF	Number Of Warrants Issued NumberOfWarrantsIssued	9875202	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.53
CY2024Q1	BIAF	Number Of Warrants Exercised NumberOfWarrantsExercised	-1036486	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8838717	shares
CY2024Q1	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	27723	usd
CY2023	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	0	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	4686	usd
CY2024Q1	us-gaap	Payments For Rent PaymentsForRent	31000	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	26000	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.007
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	14285715	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	282613	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	157613	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	0	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	8838717	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4649952	shares

Files In Submission

Name	View Source	Status
biaf-20240331_cal.xml	Edgar Link	unprocessable
0001493152-24-019615-index-headers.html	Edgar Link	pending
0001493152-24-019615-index.html	Edgar Link	pending
0001493152-24-019615.txt	Edgar Link	pending
0001493152-24-019615-xbrl.zip	Edgar Link	pending
biaf-20240331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
biaf-20240331_def.xml	Edgar Link	unprocessable
biaf-20240331_lab.xml	Edgar Link	unprocessable
biaf-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIAF
bioAffinity Technologies, Inc. Stock $biaf

2024 Q2 Form 10-Q Financial Statement

#000149315224019615 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF bioAffinity Technologies, Inc. Stock $biaf

2024 Q2 Form 10-Q Financial Statement

#000149315224019615 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIAF
bioAffinity Technologies, Inc. Stock $biaf